Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

Targeted delivery of NSC59984 via thermoresponsive nanocarriers inhibits mutant p53 in metastatic prostate cancer

Ann Maria Anto – MSc Student, Pharmacy, Queen's University Belfast; Adam Moore – MSc Student, Pharmacy, Queen's University Belfast; Wafa Al-Jamal – Professor, Pharmacy, Queen's University Belfast
Introduction:

TP53 is one of the most frequently mutated genes in prostate cancer (PC), with a higher frequency observed in advanced PC (1). High prevalence of p53 mutation imposes a risk for chemoresistance (2). NSC59984 is a potential agent to restore p53 activity through a dual mechanism: activating p73 as well as degrading p53 mutants (3). Encapsulating NSC59984 in low-temperature sensitive liposomes (LTSL) takes advantage of localised heating to trigger payload release from the carrier system, thereby preventing off-target drug release and reducing the systemic side effects (4).

Learning Objectives:

  • Investigate the use of a small molecule NSC59984 for the restoration of p53 functional pathway in prostate cancer.
  • Develop NSC59984-loaded thermoresponsive liposomal formulations.
  • Evaluate LTSL-NSC59984 effectiveness in advanced prostate cancer cell lines (2D & 3D) under mild hyperthermia.